Motoi Baba1, Masato Takahashi1, Katsushige Yamashiro2, Hideki Yokoo3, Moto Fukai3, Masanori Sato3, Mitsuchika Hosoda4, Toshiya Kamiyama3, Akinobu Taketomi3, Hiroko Yamashita5. 1. Division of Breast Surgery, Hokkaido Cancer Center, Kikusui 4-2, Shiroishi-ku, Sapporo, 003-0804, Japan. 2. Division of Pathology, Hokkaido Cancer Center, Kikusui 4-2, Shiroishi-ku, Sapporo, 003-0804, Japan. 3. Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita-ku, Sapporo, 060-8638, Japan. 4. Breast Surgery, Hokkaido University Hospital, Kita 14 Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. 5. Breast Surgery, Hokkaido University Hospital, Kita 14 Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. hirokoy@huhp.hokudai.ac.jp.
Abstract
PURPOSE: Recent studies have indicated that constitutive NF-κB activity could be involved in the proliferation of triple-negative breast cancer. METHODS: The NF-κB/p65 expression and the effects of a NF-κB inhibitor, (-)-DHMEQ, were examined in triple-negative MDA-MB-231 breast cancer cells. Women with triple-negative breast cancer treated with neoadjuvant chemotherapy between 2002 and 2012 were retrospectively analyzed for their expression of NF-κB/p65, Bcl2 and Ki67 by immunohistochemistry in pre- and post-treatment specimens. The factors predicting the response to neoadjuvant chemotherapy and the prognosis were analyzed. RESULTS: NF-κB/p65 was predominantly expressed in the cytoplasm of MDA-MB-231 cells. Of 34 triple-negative breast cancer patients, positive staining for NF-κB/p65 expression was detected in the nuclei of a few cells in seven tumors before neoadjuvant chemotherapy, while the expression of NF-κB/p65 in the cytoplasm was detected in almost all tumor cells of 33 tumors. The expression levels of NF-κB/p65 were not associated with the response to neoadjuvant chemotherapy, although the cytoplasmic NF-κB/p65 staining intensity was significantly decreased in the post-treatment tumor samples compared with the pretreatment samples. All patients whose tumors showed strong cytoplasmic NF-κB/p65 expression before neoadjuvant chemotherapy are currently disease free. CONCLUSION: Our results suggest that strong cytoplasmic NF-κB/p65 expression could be a prognostic marker for patients with triple-negative breast cancer.
PURPOSE: Recent studies have indicated that constitutive NF-κB activity could be involved in the proliferation of triple-negative breast cancer. METHODS: The NF-κB/p65 expression and the effects of a NF-κB inhibitor, (-)-DHMEQ, were examined in triple-negative MDA-MB-231 breast cancer cells. Women with triple-negative breast cancer treated with neoadjuvant chemotherapy between 2002 and 2012 were retrospectively analyzed for their expression of NF-κB/p65, Bcl2 and Ki67 by immunohistochemistry in pre- and post-treatment specimens. The factors predicting the response to neoadjuvant chemotherapy and the prognosis were analyzed. RESULTS: NF-κB/p65 was predominantly expressed in the cytoplasm of MDA-MB-231 cells. Of 34 triple-negative breast cancerpatients, positive staining for NF-κB/p65 expression was detected in the nuclei of a few cells in seven tumors before neoadjuvant chemotherapy, while the expression of NF-κB/p65 in the cytoplasm was detected in almost all tumor cells of 33 tumors. The expression levels of NF-κB/p65 were not associated with the response to neoadjuvant chemotherapy, although the cytoplasmic NF-κB/p65 staining intensity was significantly decreased in the post-treatment tumor samples compared with the pretreatment samples. All patients whose tumors showed strong cytoplasmic NF-κB/p65 expression before neoadjuvant chemotherapy are currently disease free. CONCLUSION: Our results suggest that strong cytoplasmic NF-κB/p65 expression could be a prognostic marker for patients with triple-negative breast cancer.
Entities:
Keywords:
NF-κB/p65; Neoadjuvant chemotherapy; Prognosis; Triple-negative breast cancer
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: C Montagut; I Tusquets; B Ferrer; J M Corominas; B Bellosillo; C Campas; M Suarez; X Fabregat; E Campo; P Gascon; S Serrano; P L Fernandez; A Rovira; J Albanell Journal: Endocr Relat Cancer Date: 2006-06 Impact factor: 5.678
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Gunter von Minckwitz; Wolfgang D Schmitt; Sibylle Loibl; Berit M Müller; Jens U Blohmer; Bruno V Sinn; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Hans Tesch; Jörn Hilfrich; Jens Huober; Tanja Fehm; Jana Barinoff; Thomas Rüdiger; Erhard Erbstoesser; Peter A Fasching; Thomas Karn; Volkmar Müller; Christian Jackisch; Carsten Denkert Journal: Clin Cancer Res Date: 2013-06-27 Impact factor: 12.531
Authors: Marcin Michalak; Michał S Lach; Sylwia Borska; Błażej Nowakowski; Kazuo Umezawa; Wiktoria M Suchorska Journal: Am J Cancer Res Date: 2021-12-15 Impact factor: 6.166